M. E. de la Morena-Barrio (1), A. I. Antón (1), I. Martínez-Martínez (1), J. Padilla (1), A. Miñano (1), J. Navarro-Fernández (1), S. Águila (1), M. F. López (2), J. Fontcuberta (3), V. Vicente (4), J. Corral (1)
(1) Centro Regional de Hemodonación, University of Murcia, Spain; (2) Unidad de Hemostasia y Trombosis del Complejo Hospitalario Universitario, A Coruña, Spain; (3) Unitat d'Hemostàsia i Trombosi, Departament d'Hematologia, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; (4) Centro Regional de Hemodonación, Universidad de Murcia, Spain
Antithrombin is the main endogenous anticoagulant. Impaired function or deficiency of this molecule significantly increases the risk of thrombosis. We studied the genetic variability of SERPINC1 , the gene encoding antithrombin, to identify mutations affecting regulatory regions with functional effect on its levels. We sequenced 15,375 bp of this gene, including the potential promoter region, in three groups of subjects: five healthy subjects with antithrombin levels in the lowest (75%) and highest (115%) ranges of our population, 14 patients with venous thrombosis and a moderate antithrombin deficiency as the single thrombophilic defect, and two families with type I antithrombin deficiency who had neither mutations affecting exons or flanking regions, nor gross gene deletions. Our study confirmed the low genetic variability of SERPINC1 , particularly in the coding region, and its minor influence in the heterogeneity of antithrombin levels. Interestingly, in one family, we identified a g.2143 C>G transversion, located 170 bp upstream from the translation initiation codon. This mutation affected one of the four regions located in the minimal promoter that have potential regulatory activity according to previous DNase footprinting protection assays. Genotype-phenotype analysis in the affected family and reporter analysis in different hepatic cell lines demonstrated that this mutation significantly impaired, although it did not abolish, the downstream transcription. Therefore, this is the first mutation affecting a regulatory region of the SERPINC1 gene associated with antithrombin deficiency. Our results strongly sustain the inclusion of the promoter region of SERPINC1 in the molecular analysis of patients with antithrombin deficiency.
thrombosis, polymorphisms, Antithrombin, promoter, SERPINC1
Peter Raivio1,Anne Kuitunen2, Jari Petäjä5, Sorella Ilveskero4, Riitta Lassila3,4
Thromb Haemost 2008 99 2: 427-434
G. Castaldo (1, 2), A. M. Cerbone (3), A. Guida (3), I. Tandurella (1, 2), R. Ingino (1, 2), A. Tufano (3), C. Ceglia (1, 2), M. N. D. Di Minno (3), A. L. Ruocco (3), G. Di Minno (3)
Thromb Haemost 2012 107 4: 673-680
J. M. Said (1, 2), V. Ignjatovic (3, 4), P. T. Monagle (3, 4), S. P Walker (2, 5), J. R. Higgins (1, 2, 6), S. P. Brennecke (1, 2)
Thromb Haemost 2010 103 5: 984-988
Patients receiving oral anticoagulants should be carefully managed to minimize the risk of bleeding...
Acquired haemophilia A (AHA) is a rare but often severe bleeding disorder caused by ...
Section III " Vitamin K antagonists in heart disease: Current status and perspectives" of...